Latest Breaking News On - Eradicate duchenne - Page 2 : vimarsana.com

Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceMuscular dystrophy association united statesSanthera pharmaceuticals holdingHead investor relations communicationsEuropean unionCommittee for medicinal products human useSanthera pharmaceuticalsNational institutes of healthDrug administration

Santhera Pharmaceuticals Holding AG: European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthEuropean commissionDuchenne research fundFoundation to eradicate duchenneDrug administrationSanthera pharmaceuticals holding

European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomShabir hashamEva kaliasReveragen biopharmareveragenReveragen biopharmaeric hoffmanLife science allianceMuscular dystrophy association united statesSanthera pharmaceuticals holdingEuropean unionSantherasanthera pharmaceuticalsCommittee for medicinal products human useSantherasanthera pharmaceuticals holdingSanthera pharmaceuticalsNational institutes of health

Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Switzerland generalUnited statesUnited kingdomEric hoffmanEva kaliasReveragen biopharmaDario eklundLife science allianceMuscular dystrophy association united statesSanthera pharmaceuticals holdingHead investor relations communicationsEuropean unionReveragen biopharma incSanthera pharmaceuticalsNational institutes of healthDrug administration

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they

Switzerland generalUnited statesUnited kingdomEric hoffmanEva kaliasReveragen biopharmaDario eklundReveragen biopharma incLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneDrug administrationSanthera pharmaceuticals holding